Amarin Corporation plc (NASDAQ:AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced select preliminary unaudited 2025 financial highlights, provided a summary of key 2025 operational accomplishments, and outlined 2026 priorities in advance of business development and investor meetings in San Francisco during the week of January 12, 2026.
Creating a New Operating Paradigm from a Position of Strength"Our preliminary results for the fourth quarter and full year 2025 represent an inflection point in the evolution of Amarin," said Aaron Berg, Chief Executive Officer.
"We are executing our measured and strategic approach to transforming our business and unleashing its significant untapped potential. With the exclusive, long-term partnership with Recordati S.p.A. to commercialize VAZKEPA® (icosapent ethyl) across 59 countries focused on Europe and subsequent further meaningful reduction in our operating expenses, in the fourth quarter of 2025 we achieved positive cash flow – a milestone reached earlier than previously forecasted. We believe we are on track for sustainable positive annual cash flow in 2026, driven by continued efficient revenue generation across all markets, a full year of cost savings from our restructuring plan, and the fact that the majority of the expenses associated with that plan were incurred in 2025. We have a robust cash position and debt-free balance sheet and are actively pursuing additional ways to unlock shareholder value."
2025 Select Unaudited Financial HighlightsBalance Sheet
- Year-end 2025 cash balance of $303 million, an increase of $16 million from $287 million in Q3 2025.
- Positive cash flow in Q4 2025 achieved ahead of prior expectation of 2026.
- No debt.
Income Statement
- Q4 2025 net revenue expected to range between $48 - $53 million and FY 2025 net revenue expected to range between $212 - $217 million.
- Realized approximately 50% of the $70 million in estimated OPEX savings related to the 2025 restructuring; on track to realize the full estimated savings benefit by June 30, 2026, resulting in a significantly lower operating cost structure going forward.
- Expected restructuring costs to range from $37 - $40 million, up from the prior estimate of $30 - $37 million.
2025 Key AccomplishmentsUnited States
- Sustained VASCEPA's market leadership across all available IPE products (brand and generic) with year-end 2025 share greater than 50% of IPE prescriptions.
- Maintained all major managed care exclusives throughout 2025 and successfully regained exclusive status mid-year with a large national pharmacy benefit manager.
Europe
- Entered into an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA in 59 countries, focused on Europe.
- Maintained in-market product demand growth across all commercialized European markets during the transition.
- As planned, Recordati is now fully managing European commercialization and promotion in a substantial majority of launched countries.
- Secured pricing and reimbursement in two new countries: Austria and Slovenia.
- Established regional access for more than 90% of eligible patients in Italy, thereby enabling Recordati to drive future growth.
ROW
- Realized increased year-over-year demand in all markets in which the Company's in-country partners have launched.
- Secured two new regulatory approvals: South Korea and Singapore.
Scientific Advancement
- Continued to advance scientific publications:
- Presented >10 new abstracts/posters at leading industry conferences globally.
- Published >20 new manuscripts in peer-reviewed journals.
2026 Outlook - Addressing Near-Term Priorities and Long-Term OpportunitiesMr. Berg continued, "In 2025, we refined our strategy and established a fully partnered business model ex-U.S., and we now believe that we are in the best position in recent memory to capitalize on the opportunities presented by our VASCEPA/VAZKEPA franchise in 2026 and beyond.
VASCEPA/VAZKEPA has already been prescribed more than 25 million times to millions of patients globally, as part of the effort to reduce cardiovascular disease as a leading cause of death. With approvals for cardiovascular risk reduction in over 50 countries and IP protection to 2039 in Europe, Amarin is well positioned for future long-term growth. We now operate in collaboration with seven experienced and well-established partners who have access to close to 100 markets and possess regional and in-country economies of scale, robust infrastructure and extensive commercial experience. Through this asset-light commercialization strategy, we are now delivering VASCEPA in a more focused, effective, and efficient manner to an expanded international patient population."
Comments